Novartis’ Promacta Receives FDA’s Breakthrough Therapy Designation for Severe Aplastic Anemia (SAA)

 Novartis’ Promacta Receives FDA’s  Breakthrough Therapy Designation for Severe Aplastic Anemia (SAA)

Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1

Shots:

  • The US FDA grants BT designation to Promacta (eltrombopag) + standard immunosuppressive therapy (SIT) for patients with 1L severe aplastic anemia (SAA)
  • The BT designation is based on research conducted at NIH results demonstrated complete response @6mos. (52%) & ORR (85%)
  • Promacta (eltrombopag) is a TPO receptor agonist and has received FDA’s & EU’s approval for thrombocytopenia in pediatric patients >1yr with insufficient response to corticosteroids and immunoglobulins

Click here to read full press release/ article | Ref: Novartis | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post